Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation

British Journal of Haematology
Andre TichelliG Socié

Abstract

Haematopoietic stem cell transplantation (HCT) is the treatment of choice for defined malignant and non-malignant haematological disorders. The main drawbacks of HCT are early transplant-related mortality and late complications, which interfere with patient outcome, health status and quality of life. In comparison with other post-transplant complications, cardiac or cardiovascular consequences seem to occur at a much lower frequency. Early complications are usually associated with patient history before transplantation, primary diagnosis, age of the patient and associated comorbidities, and the type of transplantation and conditioning used. Late cardiac and cardiovascular events may occur years and even decades after HCT, and are related to cardiotoxic chemotherapy, mediastinal radiation therapy, gender, age at transplantation, cardiovascular risk factors and graft-versus-host disease in allogeneic HCT. As has been observed in long-term survivors of Hodgkin lymphoma, where the incidence of cardiovascular complications emerged as a significant problem with increasing follow-up, it is anticipated that the incidence of these complications after HCT will also increase significantly with increasing follow-up of the survivors. This r...Continue Reading

References

Feb 1, 1992·International Journal of Radiation Biology·S Schultz-Hector
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C BravermanR T Lee
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Feb 15, 1990·The New England Journal of Medicine·G LucarelliF Albertini
May 1, 1981·Archives of Internal Medicine·J S GottdienerJ Ziegler
Dec 15, 1993·Annals of Internal Medicine·A TichelliB Speck
Apr 1, 1996·Chest·A O SoubaniP M Hassoun
Mar 5, 1998·Bone Marrow Transplantation·A L GilmanF Goldman
Jun 8, 1999·Pediatric Transplantation·L Legault, Y Bonny
Jul 1, 1999·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J G ReindersP C Levendag
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M GreenB C Hall
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Apr 25, 2000·Journal of Periodontology·R PattniP M Bartold
Aug 5, 2000·International Journal of Radiation Oncology, Biology, Physics·C K LeeM E Nierengarten
Jun 19, 2001·Annals of the Rheumatic Diseases·A TyndallA Gratwohl
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C MertensL L Robison
Aug 11, 2001·Lancet·N SaloojaUNKNOWN Late Effects Working Party of the European Group for Blood and Marrow Transplantation
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lucille D A DorresteijnHarry Bartelink
May 7, 2002·Annals of Internal Medicine·Pietro MurettoGuido Lucarelli
Nov 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E LipshultzSteven D Colan
Jan 4, 2003·Blood·Gérard SociéUNKNOWN Late Effects Working Party of the European Study Group for Blood and Marrow Transplantation

❮ Previous
Next ❯

Citations

Aug 30, 2008·Bone Marrow Transplantation·N S MajhailL J Burns
Jan 8, 2013·Bone Marrow Transplantation·N S Majhail, J Douglas Rizzo
Nov 26, 2009·Journal of Pediatric Hematology/oncology·David BuchbinderTheodore Moore
Mar 7, 2014·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Simone MarnitzRenate Arnold
May 21, 2014·Journal of Clinical Laboratory Analysis·Gulfer OzturkNamik Delibas
Jan 10, 2012·Seminars in Hematology·Alicia RovóUNKNOWN Late Effects Working Party of the European Group for Blood and Marrow Transplantation
Jan 10, 2012·Seminars in Hematology·Eolia BrissotMohamad Mohty
Oct 30, 2013·Cancer·Saro H Armenian, Eric J Chow
Oct 22, 2010·The American Journal of Medicine·Jeffrey Levisman, Ezra Amsterdam
Sep 16, 2015·Cancer·Zhuoyan LiAlicia Rovó
Nov 26, 2015·Bone Marrow Transplantation·A ShinoharaM Kurokawa
Sep 24, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohamad MohtyBipin N Savani
Aug 6, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eric J ChowDebra L Friedman
Mar 4, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Saro H ArmenianSmita Bhatia
Aug 27, 2014·Endocrine·Maria Felicia FaienzaAnnamaria Ventura
Feb 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bipin N SavaniA J Barrett
Sep 15, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Muzaffar H QazilbashRichard E Champlin
Sep 15, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·David I MarksJ Douglas Rizzo
Aug 8, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailLinda J Burns
Aug 6, 2011·Blood·Gerard Socié
Nov 27, 2015·International Journal of Cancer. Journal International Du Cancer·A E KeroP M Lähteenmäki
Nov 15, 2011·Diabetes Research and Clinical Practice·Hyun-Suk JungHong Gwan Seo
Apr 15, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia A FordGina Keck
Mar 28, 2018·Bone Marrow Transplantation·Christine N DuncanK Scott Baker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.